Washington, Sept 28 : An experimental drug called pertuzumab may help prolong the survival time for women with recurrent ovarian cancer, a University of Alabama at Birmingham doctor has said.
Dr. Sharmila Makhija, an associate professor in the Division of Gynecologic Oncology at the university, said that Phase II clinical trial data showed that pertuzumab added weeks to the lives of Stage III ovarian cancer patients, whose disease had returned after treatment with the existing chemotherapy regimens.